Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics

Introduction Brensocatib is an investigational, oral, reversible inhibitor of dipeptidyl peptidase-1 shown to prolong time to first exacerbation in adults with bronchiectasis. Outlined here are the clinical trial design, and baseline characteristics and treatment patterns of adult patients enrolled...

全面介紹

書目詳細資料

發表在:	ERJ Open Research
Main Authors:	James D. Chalmers, Pierre-Régis Burgel, Charles L. Daley, Anthony De Soyza, Charles S. Haworth, David Mauger, Kevin Mange, Ariel Teper, Carlos Fernandez, Dan Conroy, Mark Metersky
格式:	Article
語言:	英语
出版:	European Respiratory Society 2024-07-01
在線閱讀:	http://openres.ersjournals.com/content/10/4/00151-2024.full